Pharmacoeconomic Analysis of Empirical Therapy with Ceftazidime Alone or Combination Antibiotics for Febrile Neutropenia in Cancer Patients
- 1 January 1995
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 7 (1) , 49-62
- https://doi.org/10.2165/00019053-199507010-00006
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Ceftazidime Compared with Piperacillin and Tobramycin for the Empiric Treatment of Fever in Neutropenic Patients with Cancer: A Multicenter Randomized TrialAnnals of Internal Medicine, 1994
- Management of Fever in Patients with Cancer and Treatment-Induced NeutropeniaNew England Journal of Medicine, 1993
- Ceftazidime Monotherapy for Empiric Treatment of Febrile Neutropenic Patients: A MetaanalysisThe Journal of Infectious Diseases, 1991
- Ceftazidime Combined with a Short or Long Course of Amikacin for Empirical Therapy of Gram-Negative Bacteremia in Cancer Patients with GranulocytopeniaNew England Journal of Medicine, 1987
- Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patientsAntimicrobial Agents and Chemotherapy, 1987
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Monotherapy for empiric treatment of fever in granulocytopenic cancer patients.1986
- Ceftazidime compared to tobramycin and ticarcillin in immunocompromised haematological patientsJournal of Antimicrobial Chemotherapy, 1983
- Origin of Infection in Acute Nonlymphocytic LeukemiaAnnals of Internal Medicine, 1972
- Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute LeukemiaAnnals of Internal Medicine, 1966